FDA Accepts Takeda Pharmaceutical Co. Ltd. and H. Lundbeck A/S’s Filing for Review of Brintellix (vortioxetine) for the Treatment of Major Depression

H. Lundbeck A/S (Lundbeck) announced today that the U.S. Food and Drug Administration (FDA) has accepted the submission of a New Drug Application (NDA) for BrintellixTM (vortioxetine) for the treatment of major depressive disorder (MDD) in adult patients. Brintellix (pronounced “brin'-tel-ix”) is the proposed global trade name for vortioxetine.